Double antibody radioimmunoassay for monitoring metastatic XXXX .

@entity1 @entity1558 @entity0 @entity3
We previously reported the production of a panel of murine monoclonal antibodies which recognize glycoproteins abnormally expressed in @entity1 @entity0 . Using two of these antibodies, a double antibody radioimmunoassay was designed to quantify levels of these @entity0 marker glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion, 63% and 75% of @entity1 with @entity0 stages I and II, respectively, and 88% of those with @entity3 were found to have elevated marker levels. Thirteen percent of @entity1 with non-malignant @entity1558 also had elevated marker levels. Elevated marker levels were also detected in @entity1 with non @entity0 . One hundred and eleven @entity1 with @entity3 were followed. Eighty-two percent of those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels. These changes in marker levels preceded by up to 6 months changes in disease state. From these results we conclude that this assay may be useful for monitoring the course of disease in @entity0 @entity1 .
